BioSpace News Archive

Pliant Therapeutics, Inc. today announced senior management’s participation in the following investor events in February.

Orchestra BioMed Holdings, Inc. announced the addition of several highly accomplished industry veterans to its senior leadership team.

Viridian Therapeutics, Inc. today announced that senior management will participate in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023 at 1:00 p.m. ET.

Achieve Life Sciences, Inc. today announced that the final subject of the Company’s Phase 2 ORCA-V1 trial has completed treatment in the study.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM) today submitted its Type B meeting package with the U.S. Food and Drug Administration (“FDA”) to discuss the remaining requirements for the KETARX™ On-Body Pump System (subcutaneous racemic ketamine) and submission of a New Drug Application (“NDA”) under the 505(b)(2) pathway.

Insmed Incorporated today announced that management will present in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 12:00 p.m. ET.

Novartis Pharmaceuticals Canada Inc. today announced a collaboration with health teams in Ontario to bring together a network of secondary prevention Nurse Practitioner (NP) enabled traditional and virtual cardiology clinics in select Ontario sites.

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced the appointment of John Kauh, M.D. to the position of Chief Medical Officer.

Alto Neuroscience today announced the expansion of the company’s leadership team with the addition of Erin R. McQuade, J.D., as general counsel and chief administrative officer (CAO).

Vesigen Therapeutics, Inc. today announced the expansion of the Scientific Advisory Board with the appointments of Connie Cepko, PhD and Kate Fitzgerald, PhD.